Table 1 AR positivity in different tumors
From: Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary
Tumor | Total (M+F) | AR Positive Nuclear or Nuclear-Cytoplasmic immunoreactivity %(n) | Cytoplasmic immunoreactivity |
|---|---|---|---|
IDC | 29 (All F) | 48% (14/29) | 55%(16/29) |
ILC | 5 (All F) | 100% (5/5) | 100% (5/5) |
Ovary | 10* | 20% (2/10) | 90% (9/10) |
Endometrium | 7 | 0% (0/7) | 43%(3/7) |
Cervix | 6 | 0% (0/7) | 17%(1/6) |
Lung | 23 (6 + 17)** | 0% (0/23) | 74%(17/23) |
Colon | 9 (2+7)*** | 0% (0/9) | 78%(7/9) |
Stomach | 6 (4+2)**** | 0% (0/6) | 50%(3/6) |
Pancreas | 7 (2+5) | 0% (0/7) | 43%(3/7) |
Hepatobiliary | 11 (5+6) | 0% (0/11) | 18%(2/11) |